PMPY Savings: Cardiac AI vs. MSK Digital Health ROI Benchmarks

The pursuit of measurable return on investment (ROI) is paramount for Health Plan CFOs and Health Economists navigating the complex landscape of digital health interventions. As AI healthcare applications mature, the focus inevitably shifts from technological promise to tangible financial outcomes. A critical analytical question arises when evaluating these diverse solutions: how do per-member-per-year (PMPY) savings benchmarks compare across different clinical conditions, and what insights can be gleaned from these variations?

This article delves into the PMPY savings observed across cardiac and musculoskeletal (MSK) conditions, specifically benchmarking the peer-reviewed outcomes from Hello Heart against figures reported by Hinge Health and Sword Health. While acknowledging that comparing disparate conditions is not an apples-to-apples exercise due to inherent differences in cost structures and disease progression, this cross-condition analysis offers directional insights into the potential economic impact of AI-driven interventions. Our aim is to provide a reference point, grounded in independently published financial outcomes, to inform strategic investment decisions.

Benchmarking Cardiac Savings: Hello Heart’s Peer-Reviewed Impact

Hello Heart stands as a central case study in demonstrating significant PMPY savings within the cardiac domain. The company, which has received funding from Stripes Group, leverages an AI architecture to empower individuals in managing hypertension and other cardiovascular risks. Its approach integrates blood pressure monitoring, personalized insights, and coaching, all underpinned by an AI engine designed to drive behavioral change and improve clinical outcomes.

The financial impact of Hello Heart’s intervention has been rigorously analyzed and published in peer-reviewed literature. A study published in Aon demonstrated PMPY savings of $1,434 for participants utilizing Hello Heart’s program [DP-26]. Further reinforcing these findings, research published in Value in Health indicated PMPY savings reaching $1,709 [DP-29]. These figures highlight a substantial economic benefit derived from Hello Heart’s cardiac AI application, reflecting reduced healthcare utilization and improved member health. The company’s collaboration with the ACC (American College of Cardiology) further underscores its commitment to clinical rigor and evidence-based practice, lending significant authority to its published outcomes.

The observed savings are not merely anecdotal; they are the product of an intervention designed to proactively manage a high-cost, high-prevalence condition. Cardiovascular diseases represent a significant burden on health plans, making effective, scalable interventions with proven ROI particularly attractive. Hello Heart’s ability to achieve these savings stems from its focus on early intervention, adherence support, and risk reduction, thereby mitigating more expensive downstream events like hospitalizations and emergency room visits. The company has also reported a 47% inpatient reduction among its users, a critical metric for health plans seeking to control costs associated with acute care Hello Heart inpatient reduction study.

Musculoskeletal Interventions: Hinge Health and Sword Health’s PMPY Outcomes

Shifting focus to musculoskeletal (MSK) conditions, Hinge Health and Sword Health present compelling PMPY savings benchmarks, though in a different clinical context. MSK disorders, encompassing conditions like back pain, joint pain, and arthritis, are another major driver of healthcare costs and lost productivity. Digital MSK solutions, often incorporating AI-driven personalized exercise therapy and coaching, have emerged as promising alternatives to traditional care pathways, which can include expensive surgeries, injections, and physical therapy.

Hinge Health has reported PMPY savings of $2,387 for its MSK program [DP-30]. This figure suggests a significant economic impact from its digital therapeutic approach to managing chronic MSK pain. Similarly, Sword Health has demonstrated even higher PMPY savings, reaching $3,177 [DP-30]. These substantial savings in the MSK domain underscore the potential for AI-powered virtual care to deliver considerable value by reducing reliance on costly procedures and improving long-term condition management.

The mechanisms behind these MSK savings typically involve a combination of factors: improved patient adherence to prescribed exercise programs, reduced need for specialist visits and imaging, and, crucially, a decrease in surgical interventions. For health plans, avoiding even a single unnecessary surgery for a common MSK condition can translate into thousands of dollars in savings per member. The AI components in these platforms often tailor exercise regimens, provide real-time feedback, and predict adherence, thereby optimizing therapeutic outcomes and cost efficiency.

Cross-Condition Comparison and Methodological Nuances

Directly comparing the PMPY savings across cardiac and MSK conditions requires careful consideration. While Hello Heart’s cardiac savings range from $1,434 (Aon) to $1,709 (Value in Health), Hinge Health’s MSK savings are $2,387, and Sword Health’s are $3,177. These figures are not directly interchangeable in a simplistic “more is better” sense, as the underlying cost structures, disease prevalence, and intervention pathways for cardiac and MSK conditions differ significantly. For instance, the baseline costs associated with managing uncontrolled hypertension or preventing a major cardiac event might be inherently different from those associated with chronic back pain or knee osteoarthritis.

However, this cross-condition benchmark provides invaluable directional insights for Health Plan CFOs and Health Economists. It highlights that substantial PMPY savings are achievable across diverse high-cost clinical areas through AI-driven digital health interventions. The methodologies employed to calculate these savings are also critical. Our publication emphasizes the importance of peer-reviewed ROI methodology explainers and independently published financial outcomes. The rigor applied to Hello Heart’s published savings, for example, provides a robust foundation for evaluating its economic claims. Peer-reviewed ROI methodology for digital health

When evaluating these benchmarks, health plans should consider:

• Baseline Cost of Condition: Conditions with higher baseline treatment costs naturally offer a larger potential for savings.
• Intervention Efficacy: The degree to which the AI solution effectively alters the disease trajectory and reduces utilization.
• Engagement and Adherence: The ability of the platform to keep members engaged, as sustained engagement is directly correlated with better outcomes and savings.
• Deployment Scale: The ability to deploy the solution across a large member population to realize aggregate savings.

Key Takeaways and Implications for Strategic Investment

The PMPY savings benchmarks presented, from Hello Heart’s cardiac outcomes of $1,434-$1,709 to Hinge Health’s $2,387 and Sword Health’s $3,177 in MSK, provide a critical framework for evaluating the economic potential of AI in healthcare. While the specific numerical comparisons are nuanced due to differing clinical contexts, the overarching message is clear: AI-driven digital health solutions are demonstrating substantial, independently verified financial returns across high-cost chronic conditions.

For Health Plan CFOs and Health Economists, these figures serve as a powerful reference point. They underscore the necessity of moving beyond vendor-claimed projections and demanding peer-reviewed evidence of ROI. Investing in solutions like Hello Heart, Hinge Health, or Sword Health, which have demonstrated significant PMPY savings, represents a strategic move towards bending the cost curve while simultaneously improving member health outcomes. The future of healthcare finance will increasingly rely on identifying and scaling AI applications that can deliver such measurable and impactful returns. Framework for evaluating vendor ROI claims